ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 95 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $156,749,622 | -19.2% | 7,814,039 | +13.6% | 2.82% | -14.1% |
Q2 2023 | $194,022,823 | +249.6% | 6,877,803 | +113.1% | 3.28% | +222.1% |
Q1 2023 | $55,504,400 | +27.8% | 3,227,000 | +49.6% | 1.02% | +18.9% |
Q4 2022 | $43,432,212 | +7.7% | 2,156,515 | +15.9% | 0.86% | +7.9% |
Q3 2022 | $40,309,000 | +42.9% | 1,861,000 | +85.4% | 0.79% | +31.5% |
Q2 2022 | $28,212,000 | -19.7% | 1,004,000 | +31.9% | 0.60% | +9.6% |
Q1 2022 | $35,113,000 | -21.0% | 761,000 | +43.9% | 0.55% | -3.2% |
Q4 2021 | $44,468,000 | +26.1% | 529,000 | 0.0% | 0.57% | +22.2% |
Q3 2021 | $35,253,000 | +57.6% | 529,000 | +25.8% | 0.46% | +55.0% |
Q2 2021 | $22,365,000 | -38.0% | 420,400 | -49.5% | 0.30% | -43.9% |
Q1 2021 | $36,100,000 | -16.5% | 832,000 | 0.0% | 0.54% | -19.3% |
Q4 2020 | $43,214,000 | +49.9% | 832,000 | -8.7% | 0.66% | +17.6% |
Q3 2020 | $28,822,000 | -32.2% | 911,416 | -0.4% | 0.56% | -39.0% |
Q2 2020 | $42,496,000 | – | 914,705 | – | 0.92% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |